Most existing TE machines are bulky, costly and need to be set up in a clinic or hospital setting. Liverscan, however, combines two complex technologies in a palm-sized probe with built-in wireless Internet access capabilities. The operator needs only to install the application program on a tablet computer and then connect the probe to the Internet via Wi-Fi to start using the instrument. Liverscan is easy to use and at a fraction of the cost of other TE machines. Essentially, Liverscan makes liver fibrosis assessment more widely available to the public by lowering the cost, shortening the examination time, improving the measurement accuracy and taking the procedure out to people in the community. In March 2021, Liverscan won a silver medal at the Special Edition 2021 Inventions Geneva Evaluation Days - Virtual Event, an online version of the prestigious International Exhibition of Inventions of Geneva.
Clinical trials are now being conducted on Liverscan with a plan for local release in 2023 and a full-scale worldwide launch in 2026.